Kraków, Poland – 2 November 2018 – Selvita (WSE: SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, will participate and present at the BIO-Europe 2018 conference, which is taking place on November 5-7, 2018, in Copenhagen, Denmark.
The presentation will be held by Magdalena Marciniak, Business Alliance Manager at Selvita, on November 6, at 15:30 pm in the Room B1, on Level 0, at the Bella Center Copenhagen. Selvita will be presenting in the Drug Discovery and Development category.
Magdalena Marciniak will provide a corporate overview of the Company’s recent activities, focusing on the most recent developments of its R&D oncology programs, strategic discovery collaborations and plans for the further corporate development.
BIO-Europe is Europe’s largest partnering conference, serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. The program offers high level workshops, panels, company presentations, and a lively exhibition.
To contact Selvita’s delegates at this conference, please contact us at: firstname.lastname@example.org, or +48 539 939 584.
Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the USA (Greater Boston, San Francisco Bay), and in the UK (Cambridge). Selvita has currently several projects at early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).
+48 660 797 362